MacroGenics is pursuing alliances to participate in development of its proprietary product candidates and technology platforms.
Learn moreSince its founding in 2000, MacroGenics has applied its world-class antibody capabilities to create life-changing medicines. The company’s innovative product candidates leverage its fully-integrated capabilities and its multiple, proprietary technology platforms.
Learn more 2007 News Archive
December 01, 2007 | Nature Biotechnology
Antivirals Become A Broader Enterprise
October 19, 2007 | Washington Post
Rockville Firm Deals Drug Rights to Lilly
October 19, 2007 | BioWorld Today
MacroGenics, Lilly Ink $1B Deal For Diabetes Drug Teplizumab
October 18, 2007 | Washington Business Journal
MacroGenics To Sell Rights To Lead Product To Eli Lilly
August 03, 2007 | Washington Business Journal
MacroGenics Begins Final Testing Of Diabetes Drug
January 04, 2007 | Washington Business Journal
MacroGenics Wins $2M Grant For Diabetes Drug
News Archive: 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | View All